Ieq Capital LLC acquired a new position in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 33,915 shares of the company's stock, valued at approximately $206,000. Ieq Capital LLC owned approximately 0.07% of CryoPort as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. MetLife Investment Management LLC lifted its position in CryoPort by 13.8% during the first quarter. MetLife Investment Management LLC now owns 24,641 shares of the company's stock worth $150,000 after buying an additional 2,980 shares in the last quarter. Walleye Capital LLC lifted its position in CryoPort by 21.7% during the first quarter. Walleye Capital LLC now owns 38,021 shares of the company's stock worth $231,000 after buying an additional 6,776 shares in the last quarter. Hsbc Holdings PLC lifted its position in CryoPort by 96.7% during the first quarter. Hsbc Holdings PLC now owns 62,405 shares of the company's stock worth $419,000 after buying an additional 30,671 shares in the last quarter. Versor Investments LP purchased a new position in CryoPort during the first quarter worth approximately $177,000. Finally, Philadelphia Trust Co. purchased a new position in CryoPort during the first quarter worth approximately $589,000. Hedge funds and other institutional investors own 92.90% of the company's stock.
Insider Buying and Selling
In related news, Director Ramkumar Mandalam sold 40,728 shares of the business's stock in a transaction on Tuesday, July 22nd. The stock was sold at an average price of $7.24, for a total transaction of $294,870.72. Following the completion of the transaction, the director directly owned 92,328 shares of the company's stock, valued at $668,454.72. The trade was a 30.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jerrell Shelton sold 151,304 shares of the business's stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $6.81, for a total value of $1,030,380.24. Following the transaction, the chief executive officer directly owned 912,419 shares of the company's stock, valued at $6,213,573.39. The trade was a 14.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 449,413 shares of company stock valued at $3,160,008. Company insiders own 10.00% of the company's stock.
Analyst Upgrades and Downgrades
CYRX has been the topic of a number of analyst reports. BTIG Research reduced their price objective on CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, July 7th. Leerink Partners upgraded CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 target price on the stock in a research report on Wednesday, August 6th. KeyCorp upgraded CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 target price on the stock in a research report on Wednesday, August 6th. Stephens assumed coverage on CryoPort in a research report on Tuesday, July 22nd. They issued an "overweight" rating and a $13.00 target price on the stock. Finally, Leerink Partnrs upgraded CryoPort from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $12.00.
View Our Latest Stock Report on CYRX
CryoPort Trading Down 8.8%
Shares of NASDAQ CYRX traded down $0.83 during trading on Friday, reaching $8.64. The stock had a trading volume of 1,081,340 shares, compared to its average volume of 518,306. CryoPort, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $10.46. The company has a debt-to-equity ratio of 0.39, a quick ratio of 15.47 and a current ratio of 16.24. The business's 50-day moving average price is $8.23 and its 200-day moving average price is $6.90. The company has a market cap of $432.60 million, a P/E ratio of 6.50 and a beta of 1.62.
CryoPort (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09). CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. The firm had revenue of $45.45 million during the quarter, compared to analyst estimates of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. On average, equities research analysts predict that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.
CryoPort Company Profile
(
Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
See Also

Before you consider CryoPort, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CryoPort wasn't on the list.
While CryoPort currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.